Terug naar bedrijfspagina

Nieuws over ImmuPharma

29/09/2021 ImmuPharma - Interim Results Announcement for the six months ended 30 June 2021 (29.09.2021)

12/08/2021 IMMUPHARMA - FDA keurt de Lupzuor™ PK-studie goed (12.08.2021)

24/06/2021 ImmuPharma - FDA to agree on the Lupzuor™ PK study via a written response to “Type C” meeting as Avion prepares for international Phase 3 trial (24.06.2021)

29/04/2021 IMMUPHARMA - AANKONDIGING VAN DE EINDRESULTATEN voor de twaalf maanden eindigend op 31 december 2020 (29.04.2021)

18/02/2021 Dr. Navid Malik van Life Sciences Division geeft zijn mening en vooruitzichten op ImmuPharma PLC

16/02/2021 IMMUPHARMA - de weg vrij voor de start van de Fase III-studie in H2 2021 (16.02.2021)

11/02/2021 Header image ImmuPharma 'now have clear regulatory path through to starting Phase 3 trial for Lupuzor' (11.02.2021)

09/02/2021 Immupharma - Lupuzor sheduled to commence international Phase 3 trial (09.02.2021)

10/11/2020 2020 09 - Wachten op de Amerikaanse toezichthouder

30/09/2020 Immupharma - INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2020 (30.9.2020)

27/07/2020 ImmuPharma - Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients (27.3.2020)

14/05/2020 ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor (14.5.2020)

20/04/2020 2020 04 - Interview ImmuPharma met ceo Dimitri Dimitriou

07/04/2020 ImmuPharma to present live on ‘Investor Meet Company’ platform (6.4.2020)